Semaglutide
CompletedEfficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels
Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipid Profile- the Role of Baseline Vitamin D Levels
Lead sponsor
Asset
Semaglutide
GLP-1 agonist
Listed sites
1
Recruiting sites
-
Actual enrollment
5,300
Study population
Type 2 diabetes
Eligibility highlights
-
Primary endpoints
•BMI, change•HbA1c, change•Lipid control
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Study population text
diabetic patients on semaglutide treatment and with available baseline vitamin D levels
Inclusion criteria
Exclusion criteria
Endpoints (3)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
1 endpointrelative weight loss measured by BMI
Time frame:12 months from semaglutide initiation
BMI, change
percent change from baseline, improvement
Glycemic / diabetes
1 endpointglycemic control using Hgb1C
Time frame:12 months from semaglutide initiation
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Cardiometabolic biomarkers
1 endpointlipid control using LDL and TG
Time frame:12 months from semaglutide initiation
descriptive, improvement
Publications (17)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- Journal of diabetes investigation2022 Jul (month)PMID35174649doi:10.1111/jdi.13773via CT.gov background
- Diabetes therapy : research, treatment and education of diabetes and related disorders2022 Jun (month)PMID35532859doi:10.1007/s13300-022-01265-5via CT.gov background
- Diabetes therapy : research, treatment and education of diabetes and related disorders2022 Feb (month)PMID35044569doi:10.1007/s13300-021-01201-zvia CT.gov background
- The New England journal of medicine2021 Mar 18PMID33567185doi:10.1056/NEJMoa2032183via CT.gov background
- European journal of endocrinology2019 Sep (month)PMID31344685doi:10.1530/EJE-19-0156via CT.gov background
- Diabetes & metabolism journal2019 Aug (month)PMID30604598doi:10.4093/dmj.2018.0070via CT.gov background
- Medicina (Kaunas, Lithuania)2019 Jul 12PMID31336940doi:10.3390/medicina55070368via CT.gov background
- The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2018 Dec (month)PMID34861016doi:10.1177/8755122518790925via CT.gov background
- Nutrition research (New York, N.Y.)2018 Nov (month)PMID30442233doi:10.1016/j.nutres.2018.07.011via CT.gov background
- Journal of diabetes investigation2016 Apr (month)PMID27186364doi:10.1111/jdi.12490via CT.gov background
- Current diabetes reports2015 Jun (month)PMID25944304doi:10.1007/s11892-015-0602-9via CT.gov background
- Diabetes, obesity & metabolism2014 Oct (month)PMID24655583doi:10.1111/dom.12293via CT.gov background
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.